Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.49 |
| ▸ | CIT | O14578 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | STK10 | O94804 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | HCK | P08631 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL726475 | 1.00 | EGFR (0.57) | EGFRERBB2KDRERBB4CIT | |
| SCHEMBL726473 | 1.00 | EGFR (0.57) | EGFRERBB2KDRERBB4CIT | |
| SCHEMBL1192055 | 0.92 | EGFR (0.57) | EGFRERBB2KDRERBB4JAK3 | |
| SCHEMBL1192053 | 0.92 | EGFR (0.57) | EGFRERBB2KDRERBB4JAK3 | |
| SCHEMBL1192050 | 0.92 | EGFR (0.57) | EGFRERBB2KDRERBB4JAK3 | |
| SCHEMBL232622 | 0.91 | EGFR (0.54) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL175533 | 0.91 | EGFR (0.54) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL29623467 | 0.91 | EGFR (0.54) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL232621 | 0.91 | EGFR (0.54) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL185488 | 0.90 | EGFR (0.53) | EGFRERBB2ERBB4CITGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180360834-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-12-20 | — | — | US | claimed |
| US-20170112835-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2017-04-27 | — | — | US | claimed |
| EP-1345910-B9 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2014-06-04 | — | — | EP | claimed |
| EP-2340837-A1 | Combination treatment of cancer comprising EGFR/HER2 inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-06 | — | — | EP | claimed |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-14 | — | — | US | claimed |
| US-20090306101-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | claimed |
| US-20090306044-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | claimed |
| EP-2112140-A1 | Chinazolin derivatives, medicine containing these compounds, application thereof and method for their production | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-10-28 | — | — | EP | claimed |
| EP-1345910-B1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-04-29 | — | — | EP | claimed |
| EP-1948180-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-07-30 | — | — | EP | claimed |
| WO-2007054551-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-18 | — | — | WO | claimed |
| US-20060100223-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | claimed |
| EP-1345910-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-09-24 | — | — | EP | claimed |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | claimed |
| WO-2002050043-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | WO | claimed |
| US-20180360834-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-12-20 | — | — | US | disclosed |
| US-20180086744-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| EP-1345910-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002050043-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360834-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | NQO2, NRAS, ABL1 | EGFR 1758/4885ERBB2 1557/4885KDR 2427/4885 |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | MAP3K1, MAP4K2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 195/4885ERBB2 78/4885KDR 928/4885 |
| US-20060100223-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, RET, ABL1 | EGFR 200/4885ERBB2 122/4885KDR 654/4885 |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, ABL1, TYK2 | EGFR 218/4885ERBB2 109/4885KDR 643/4885 |
| US-20090306044-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | NQO2, NRAS, ABL1 | EGFR 1758/4885ERBB2 1557/4885KDR 2427/4885 |
| US-20170112835-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | NQO2, NRAS, ABL1 | EGFR 1758/4885ERBB2 1557/4885KDR 2427/4885 |
| US-20180086744-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885KDR 47/4885 |
| US-20090306101-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885KDR 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.